Please use this identifier to cite or link to this item:
http://dspace.mediu.edu.my:8181/xmlui/handle/123456789/4949Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.creator | Babić Nikola | - |
| dc.creator | Andreić Veljko | - |
| dc.creator | Miljković Aleksandar | - |
| dc.creator | Čanadanović Vladimir | - |
| dc.creator | Barišić Sava | - |
| dc.date | 2011 | - |
| dc.date.accessioned | 2013-05-30T12:00:45Z | - |
| dc.date.available | 2013-05-30T12:00:45Z | - |
| dc.date.issued | 2013-05-30 | - |
| dc.identifier | http://www.doiserbia.nb.rs/img/doi/0025-8105/2011/0025-81051106310B.pdf | - |
| dc.identifier | http://www.doaj.org/doaj?func=openurl&genre=article&issn=00258105&date=2011&volume=64&issue=5-6&spage=310 | - |
| dc.identifier.uri | http://koha.mediu.edu.my:8181/jspui/handle/123456789/4949 | - |
| dc.description | Introduction. This study was aimed at evaluating the safety and efficacy of brinzolamide 1% suspension (Azopt® 1%) and travoprost 0.004% (Travatan®) combined therapy in patients with open-angle glaucoma or ocular hypertension who are in need of additional intraocular pressure lowering. Material and methods. This is a prospective, three-month, open-label, clinical study. Forty patients (80 eyes) with primary open-angle glaucoma or ocular hypertension on Travatan® treatment and with unsatis-factory results in lowering intraocular pressure were included in the study. The qualifying intraocular pressure on previous treatment with Travatan® (at least 6 weeks) was 22-36 mmHg in at least one eye at 8 a.m. intraocular pressure measurements at three eligibility visits. The patients received brinzolamide 1% twice a day in addition to travoprost 0.004% given once a day in the evening for 3 months. The follow-up examinations assessing the safety and efficacy of combined therapy of brinzolamide 1% and travoprost 0.004% were performed after 1 and 3 months. Results. Adjunctive therapy with brinzolamide resulted in statistically significant reductions in intraocular pressure from the travoprost baseline at all visits. Treatment with brinzolamide/travoprost caused statistically significant sustained reduction in intraocular pressure with the reduction of 17.39% (p<0.001) after 4 weeks and 20.08% (p<0.001) after 12 weeks. The intraocular pressure change from the baseline ranged from -3.9 mmHg after 4 weeks to -4.48 mmHg after 12 weeks. The most frequently related adverse effect was abnormal taste and blurred vision. Conclusion. Brinzolamide 1% (b.i.d.) used adjunctively with travoprost 0.004% (q.d.) lowers intraocular pressure significantly compared to travoprost alone. Both drugs were well tolerated and safe in the studied patients. | - |
| dc.publisher | Društvo lekara Vojvodine Srpskog lekarskog društva | - |
| dc.source | Medicinski Pregled | - |
| dc.subject | Glaucoma | - |
| dc.subject | Open-Angle | - |
| dc.subject | Ocular Hypertension | - |
| dc.subject | Drug Therapy | - |
| dc.subject | Combination | - |
| dc.subject | Glaucoma | - |
| dc.subject | Intraocular Pressure | - |
| dc.title | Adjunctive therapy with brinzolamide in patients on travoprost treatment | - |
| Appears in Collections: | Health Sciences | |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.